Effects of palbociclib on oral squamous cell carcinoma and the role of PIK3CA in conferring resistance

查看全文 作　　者：Nur Syafinaz [1,2]Zainal;Bernard Kok Bang [1,2]Lee;Zheng Wei [1]Wong;Iuan Sheau [1]Chin;Pei San [1,2]Yee;Chai Phei [1]Gan;Kein Seong [3]Mun;Zainal Ariff Abdul [2,4]Rahman;J. Silvio [5]Gutkind;Vyomesh [1]Patel;Sok Ching [1,2]Cheong

机构地区：[1]Head and Neck Team, Cancer Research Malaysia, Selangor 47500, Malaysia;[2]Department of Oral & Maxillofacial Clinical Sciences, Faculty of Dentistry, University of Malaya, Kuala Lumpur 50603, Malaysia;[3]Department of Pathology, Faculty of Medicine, University of Malaya, Kuala Lumpur 50603, Malaysia;[4]Oral Cancer Research and Co-ordinating Centre (OCRCC), Faculty of Dentistry, University of Malaya, Kuala Lumpur 50603, Malaysia;[5]Department of Pharmacology, University of California, San Diego 92093-5004, CA, USA

出　　处：《Cancer Biology & Medicine》索引2019年第16卷第2期,共12页

基　　金：supported by a grant from High Impact Research, Ministry of Higher Education (HIR-MOHE) from University of Malaya (Grant No. UM.C/625/1/HIR/MOHE/ DENT-03);Cancer Research Malaysia 摘　　要：Objective: Lack of effective therapies remains a problem in the treatment of oral squamous cell carcinoma(OSCC), especially in patients with advanced tumors. OSCC development is driven by multiple aberrancies within the cell cycle pathway, including amplification of cyclin D1 and loss of p16. Hence, cell cycle inhibitors of the CDK4/6-cyclin D axis are appealing targets for OSCC treatment. Here, we determined the potency of palbociclib and identified genetic features that are associated with the response of palbociclib in OSCC.Methods: The effect of palbociclib was evaluated in a panel of well-characterized OSCC cell lines by cell proliferation assays and further confirmed by in vivo evaluation in xenograft models. PIK3CA-mutant isogenic cell lines were used to investigate the effect of PIK3CA mutation towards palbociclib response.Results: We demonstrated that 80% of OSCC cell lines are sensitive to palbociclib at sub-micromolar concentrations.Consistently, palbociclib was effective in controlling tumor growth in mice. We identified that palbociclib-resistant cells harbored mutations in PIK3CA. Using isogenic cell lines, we showed that PIK3CA mutant cells are less responsive to palbociclib as compared to wild-type cells with concurrent upregulation of CDK2 and cyclin E1 protein levels. We further demonstrated that the combination of a PI3 K/mTOR inhibitor(PF-04691502) and palbociclib completely controlled tumor growth in mice.Conclusions: This study demonstrated the potency of palbociclib in OSCC models and provides a rationale for the inclusion of PIK3CA testing in the clinical evaluation of CDK4/6 inhibitors and suggests combination approaches for further clinical studies. 关键词：OSCC palbociclib CDK4/6 INHIBITORS PIK3CA

相关文献

参考文献（32）
引证文献（5）
耦合文献（0）

参考文献(32)

引证文献(5)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Effects of palbociclib on oral squamous cell carcinoma and the role of PIK3CA in conferring resistance

参考文献(32)

引证文献(5)

用户提示